CN102198118A - 一种治疗呕吐的口腔药物制剂及其制备方法 - Google Patents
一种治疗呕吐的口腔药物制剂及其制备方法 Download PDFInfo
- Publication number
- CN102198118A CN102198118A CN201110075948XA CN201110075948A CN102198118A CN 102198118 A CN102198118 A CN 102198118A CN 201110075948X A CN201110075948X A CN 201110075948XA CN 201110075948 A CN201110075948 A CN 201110075948A CN 102198118 A CN102198118 A CN 102198118A
- Authority
- CN
- China
- Prior art keywords
- preparation
- alizapride
- film
- solution
- vomiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 230000008673 vomiting Effects 0.000 title claims abstract description 19
- 210000004916 vomit Anatomy 0.000 title abstract description 4
- KSEYRUGYKHXGFW-UHFFFAOYSA-N 6-methoxy-N-[(1-prop-2-enyl-2-pyrrolidinyl)methyl]-2H-benzotriazole-5-carboxamide Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003687 alizapride Drugs 0.000 claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 18
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000003729 cation exchange resin Substances 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 7
- 239000000811 xylitol Substances 0.000 claims abstract description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 7
- 229960002675 xylitol Drugs 0.000 claims abstract description 7
- 235000010447 xylitol Nutrition 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 5
- 239000000576 food coloring agent Substances 0.000 claims abstract description 4
- 206010047700 Vomiting Diseases 0.000 claims description 19
- 239000010408 film Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 6
- 239000001055 blue pigment Substances 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 239000001054 red pigment Substances 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000010409 thin film Substances 0.000 claims description 3
- 101100412856 Mus musculus Rhod gene Proteins 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229920001429 chelating resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 5
- 210000003296 saliva Anatomy 0.000 abstract description 4
- 210000000214 mouth Anatomy 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 abstract 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000005223 Alkalosis Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000027601 Inner ear disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 208000000689 peptic esophagitis Diseases 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 208000027491 vestibular disease Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种治疗呕吐的口腔药物制剂及其制备方法,其主药是阿立必利,辅料是聚乙烯基吡咯烷酮和低分子量的羟丙基纤维素,聚乙二醇400,阳离子交换树脂,木糖醇,FD&C食用蓝色色素1号及FD&C食用红色色素40号,本发明的优点在于:所制备的阿立必利口腔速溶制剂,在口腔中遇到唾液时能迅速溶解。在药物变成液体后,可迅速经胃肠道吸收进入体循环,口感良好,无砂粒感和苦涩感。这种膜剂与市场上现有的阿立必利片剂相比,具有更快的溶解速度和起效效果,为迅速缓解呕吐症状提供了方便。本发明采用的溶液涂布法为国内制药行业首创的生产工艺,生产的药物质量稳定,生产效率高,成本低,市场前景极为广阔。
Description
技术领域
本发明涉及一种治疗呕吐的口腔药物制剂及其制备方法,特别是一种主药为阿立必利的口腔速溶制剂及其制备方法。
背景技术
呕吐是临床常见症状恶心,常为呕吐的前驱感觉,也可单独出现表现上腹部特殊不适感,常伴有头晕、流涎、脉缓、血压降低等,迷走神经兴奋症状。呕吐是指胃内容物或一部分小肠内容物通过食管逆流出口腔的一种复杂的反射动作,呕吐可将有害物质从胃排出人而起保护作用,但持久而剧烈的呕吐可引起技水电解质紊乱。呕吐一般分反射性,中枢性,前庭障碍性,神经官能性四大类。
由于呕吐的病因复杂多样、呕吐发生和持续的时间不同、程度不等和年龄各异,所以,对机体产生的影响非常悬殊。轻者没有任何影响,仅一过性不适。长期慢性呕吐。可致消化性食管炎、低血容量、低钾、低钠、碱中毒等代谢紊乱。进一步则贫血、营养不良、生长发育停滞。急重时可引起水电解质平衡紊乱、休克或误吸、窒息、诱发心律不剂甚至死亡。因外科原因引起者还可导致消化道穿孔、弥漫性腹膜炎、休克、败血症等严重后果。那些运动神经功能不良的病儿也极易发生呕吐后误吸,需倍加警惕。
阿立必利是一种强效抗呕吐药物,口服生物利用率高达80%以上。但是目前市场上的阿立必利口服药物以片剂为主,患者服药时需用大量水送服,对于呕吐症状患者来说吞咽十分不便。
发明内容
本发明的目的是提供一种服用方便,溶解迅速的阿立必利口腔速溶制剂,该制剂在口腔中能迅速溶解于唾液而无需饮水,尤其适用于呕吐症状的治疗。药物在溶解后可迅速经胃肠道吸收进入体循环,使一些吞咽困难的呕吐患者能够方便地使用阿立必利药物。
本发明的另一目的是提供上述制剂的制备方法。
一种治疗呕吐的口腔药物制剂,其主药是阿立必利,辅料是聚乙烯基吡咯烷酮和低分子量的羟丙基纤维素,聚乙二醇400,阳离子交换树脂,木糖醇,FD&C食用蓝色色素1号及FD&C食用红色色素40号。各组分重量比:
所述的阳离子树脂的型号为美国罗门哈斯公司Amberlite IRA400。
本发明制剂的制备工艺,按以下步骤进行:
a)将主药阿立必利溶于无水乙醇,加入阳离子交换树脂,搅拌均匀;
b)减压蒸馏出去无水乙醇,制成阿立必利/阳离子交换树脂复合物,得到复合物2;
c)将聚乙烯基吡咯烷酮和低分子量的羟丙基纤维素加入适量40℃水中搅拌溶解,得到溶液4;
d)加入40℃水调节该水溶液粘度至1000~30000cps;
e)剧烈搅拌下将复合物2加入溶液4,继续搅拌至溶液均匀;
f)加入木糖醇和食用色素搅拌均匀;
g)减压脱去气泡,待用;
h)将脱去气泡的溶液转移至涂布机机头,涂布在基质为防粘纸表面,成为均匀的膜;
i)将涂布好的膜传送进入鼓风烘箱,在50~80℃温度下除去水分,制成厚度为25~250微米的固体薄膜;
j)将烘好的薄膜切割成合适大小,每片薄膜重量约为50~200毫克。
本发明采用溶液涂布法在涂布机上制备阿立必利口腔速溶膜制剂,提高了药物的稳定性和生产效率。
本发明的使用方法:
将口腔速溶药膜置于舌上或舌下,1分钟内迅速溶解于唾液,完成服药过程。
本发明的优点在于:所制备的阿立必利口腔速溶制剂,在口腔中遇到唾液时能迅速溶解。药物变成液体后,可迅速经胃肠道吸收进入体循环,口感良好,无砂粒感和苦涩感。这种膜剂与市场上现有的阿立必利片剂相比,具有更快的溶解速度和起效效果,为迅速缓解呕吐症状提供了方便。本发明采用的溶液涂布法为国内制药行业首创的生产工艺,生产的药物质量稳定,生产效率高,成本低,市场前景极为广阔。
具体实施方式:
下面结合实施例对本发明作详细的说明。
实施例1:
处方:
本实施例主药为阿立必利,高分子聚合物成膜剂为聚乙烯基吡咯烷酮和羟丙基纤维素,聚乙二醇400是增塑剂,阳离子交换树脂和木糖醇是掩味剂,FD&C食用蓝色色素1号和红色色素40号是用于增加膜剂的外观美感。
本实施例的制备工艺,通过以下步骤进行:
1.按上述处方中主药5g阿立必利溶于100g无水乙醇,加入阳离子交换树脂,搅拌4小时;
2.旋转减压蒸馏出去无水乙醇,制成阿立必利/阳离子交换树脂复合物;
3.上述辅料12.7g聚乙烯基吡咯烷酮和17.9g低分子量的羟丙基纤维素加入180g 40℃水中搅拌2小时;
4.加入20g 40℃水调节该水溶液粘度至8400cps;
5.剧烈搅拌下将复合物2加入溶液4,继续搅拌2小时;
6.搅拌下加入7.6g木糖醇,0.02g FD&C食用蓝色色素1号和FD&C食用红色色素40号搅拌30分钟;
7.减压脱去气泡,待用;
8.将溶液7转移至涂布机机头,涂布在作为基质的防粘纸表面成均匀的膜;
9.传送进入鼓风烘箱,在50~80℃温度下除去水分,制成厚度为50微米的固体薄膜;
10.将薄膜切割成长25毫米,宽15毫米的小片,每片薄膜重量约为75毫克。
实施例2:
处方:
本实施例的制备工艺与实施例1中相同,最后得到的薄膜厚度为25微米。切割成长3厘米,宽2厘米的小片,每片薄膜重量为50毫克。
实施例1、2的技术指标如下:
将阿立必利口腔速溶药膜放入37℃的50ml恒温水浴中,秒表计时,完全溶解时间小于1分钟。
Claims (3)
2.根据权利要求1所述的一种治疗呕吐的口腔药物制剂,其特征在于:所述的阳离子树脂的型号为美国罗门哈斯公司Amberlite IRA400。
3.权利要求1所述的一种治疗呕吐的口腔药物制剂的制备方法,按以下步骤进行:
a)将主药阿立必利溶于无水乙醇,加入阳离子交换树脂,搅拌均匀;
b)减压蒸馏出去无水乙醇,制成阿立必利/阳离子交换树脂复合物,得到复合物2;
c)将聚乙烯基吡咯烷酮和低分子量的羟丙基纤维素加入适量40℃水中搅拌溶解,得到溶液4;
d)加入40℃水调节该水溶液粘度至1000~30000cps;
e)剧烈搅拌下将复合物2加入溶液4,继续搅拌至溶液均匀;
f)加入木糖醇和食用色素搅拌均匀;
g)减压脱去气泡,待用;
h)将脱去气泡的溶液转移至涂布机机头,涂布在基质为防粘纸表面,成为均匀的膜;
i)将涂布好的膜传送进入鼓风烘箱,在50~80℃温度下除去水分,制成厚度为25~250微米的固体薄膜;
j)将烘好的薄膜切割成合适大小,每片薄膜重量约为50~200毫克。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110075948A CN102198118B (zh) | 2011-03-28 | 2011-03-28 | 一种治疗呕吐的口腔药物制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110075948A CN102198118B (zh) | 2011-03-28 | 2011-03-28 | 一种治疗呕吐的口腔药物制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102198118A true CN102198118A (zh) | 2011-09-28 |
CN102198118B CN102198118B (zh) | 2012-08-29 |
Family
ID=44659276
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110075948A Expired - Fee Related CN102198118B (zh) | 2011-03-28 | 2011-03-28 | 一种治疗呕吐的口腔药物制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102198118B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657604A (zh) * | 2012-04-20 | 2012-09-12 | 苏州爱斯欧蒂生物科技有限公司 | 治疗眩晕呕吐的口服液 |
CN104013606A (zh) * | 2014-06-24 | 2014-09-03 | 万特制药(海南)有限公司 | 一种氢溴酸右美沙芬膜剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5032393A (en) * | 1988-05-11 | 1991-07-16 | Glaxo Group Limited | Drug adsorbates |
CN1418624A (zh) * | 2002-12-19 | 2003-05-21 | 王登之 | 治疗呕吐的阿立必利口腔崩解片及其制备方法 |
-
2011
- 2011-03-28 CN CN201110075948A patent/CN102198118B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5032393A (en) * | 1988-05-11 | 1991-07-16 | Glaxo Group Limited | Drug adsorbates |
CN1418624A (zh) * | 2002-12-19 | 2003-05-21 | 王登之 | 治疗呕吐的阿立必利口腔崩解片及其制备方法 |
Non-Patent Citations (2)
Title |
---|
《中国药房》 20101231 施亮 等 化疗所致恶心呕吐及其治疗药物的研究进展 3633-3635页 1-3 第21卷, 第38期 * |
《实用中西医结合杂志》 19971231 李斌 止吐剂的临床进展 1234-1236页 1-3 第10卷, 第13期 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657604A (zh) * | 2012-04-20 | 2012-09-12 | 苏州爱斯欧蒂生物科技有限公司 | 治疗眩晕呕吐的口服液 |
CN104013606A (zh) * | 2014-06-24 | 2014-09-03 | 万特制药(海南)有限公司 | 一种氢溴酸右美沙芬膜剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102198118B (zh) | 2012-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210267934A1 (en) | Cannabinoid oral dispersible film strip | |
US12011504B2 (en) | Blend compositions for oral administration as a rapidly dissolving powder and/or suspension | |
WO2018077310A1 (zh) | 一种含维生素c钠的泡腾片及其制备方法 | |
CN105997955B (zh) | 一种帕洛诺司琼口腔膜剂及其制备方法 | |
WO2002096406A1 (fr) | Compositions medicinales | |
ES2736183T3 (es) | Composición de absorción oro-bucal para neuro-protector | |
WO2018077311A1 (zh) | 一种缓解视疲劳的组合物及其制备方法 | |
TWI820673B (zh) | 布瑞哌唑口溶膜組合物、其製備方法及用途 | |
CN102198118B (zh) | 一种治疗呕吐的口腔药物制剂及其制备方法 | |
TW200812594A (en) | Medicine for prevention of and/or recovery from fatigue | |
JPWO2006129668A1 (ja) | 糖衣を施した丸剤 | |
US7662364B2 (en) | Drug for hyperphospheremia and its preparative method | |
KR100927254B1 (ko) | 분지쇄 아미노산을 포함하는 액상 조성물 및 이의 제조방법 | |
CN109414407B (zh) | 蒙脱石混悬液及其制备方法 | |
CN107174580A (zh) | 一种盐酸二甲双胍/盐酸小檗碱复方缓释混悬制剂及其制备方法 | |
CN1634061A (zh) | 双酚伪麻药物制剂及其制备方法 | |
CN102138915A (zh) | 一种口服药物制剂及其制备方法 | |
CN101427999B (zh) | 呋塞米口服溶液及其制备方法 | |
CN105147623A (zh) | 一种乳果糖口服冻干粉及其制备方法 | |
Almajidi et al. | An overview on oroslippery technique as a promising alternative for tablets used in Dysphagia | |
CN103432089A (zh) | 一种盐酸二甲双胍咀嚼片及其制备方法 | |
US20100120776A1 (en) | Carbocysteine medical foods | |
WO2019239420A1 (en) | Novel dosage forms of lactulose | |
CN105147632A (zh) | 一种苯巴比妥口腔崩解片及其制备方法 | |
JP2007314440A (ja) | 体力増強剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190621 Address after: 322099 Gaochuang Park, Building C, 1F West, No. 10 Gaoxin Road, Fujiang Street, Yiwu City, Zhejiang Province Patentee after: Yiwu beiken new Mstar Technology Ltd Address before: 241000 Central City B4-3-601, Yijiang District, Wuhu City, Anhui Province Patentee before: Yu Xiaoyong |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120829 Termination date: 20200328 |
|
CF01 | Termination of patent right due to non-payment of annual fee |